Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.KineMed, a translational and personalized medicine development company, has entered into a two year collaboration agreement with Bristol-Myers Squibb in the area of Alzheimer's disease and other neurodegenerative conditions. KineMed’s stable isotope technology will be used to identify novel biomarkers, which will be used to assess the extent and treatment of Alzheimer's disease.
Subscribe to our email newsletter
KineMed’s stable isotope technology is a translational and personalized medicine platform to identify and characterize novel biomarkers in cerebrospinal fluid to facilitate development of new drugs for the treatment of Alzheimer’s disease for Bristol-Myers Squibb.
Francis Cuss, MD and Senior Vice President of discovery and exploratory clinical research at Bristol-Myers Squibb, said: “KineMed has a unique approach to identifying biomarkers for neurodegenerative diseases. We value KineMed’s expertise in this area and look forward to working together in the fight against neurodegenerative diseases.”
Robert B. Stein, CEO of KineMed, said: “we are very enthusiastic about working with Bristol-Myers Squibb as we believe our expertise and platform are most powerful when applied in the context of important drug R&D programs.”